Dianthus Therapeutics Releases Interim Phase 3 Trial Results for CIDP Treatment

Dianthus Therapeutics has provided an update on its Phase 3 CAPTIVATE trial for claseprubart, a drug targeting chronic inflammatory demyelinating polyneuropathy (CIDP). The company's corporate presentation now includes interim responder analysis data from the initial 40 patients who completed the first part of the study. This update offers early insights into the drug's performance in a late-stage clinical trial.